Analysis of the scope of indications and main diseases treated by Sunitinib (Sutent)

Sunitinib (Sunitinib, trade name: Sutent) is an oral multi-target tyrosine kinase inhibitor that can inhibit angiogenesis-related VEGFR, PDGFR and various other receptor kinases. By blocking tumor angiogenesis and cell signaling, sunitinib can effectively inhibit tumor growth and metastasis, and is widely used in the targeted therapy of a variety of malignant tumors.

Sunitinib is one of the first-choice targeted drugs for advanced or metastatic clear cell renal cell carcinoma. For patients with unresectable or postoperative recurrence, sunitinib can delay disease progression and improve progression-free survival (PFS) and overall survival (OS). Its oral administration method facilitates long-term maintenance treatment and has shown significant efficacy in multiple clinical trials.

Sunitinib is also suitable for the second-line treatment of gastrointestinal stromal tumors (GIST). For patients who are resistant or intolerant to imatinib, sunitinib can be used as an alternative to inhibit tumor growth. In addition, it has also been used to treat rare solid tumors such as pancreatic neuroendocrine tumors (pNET), showing broad-spectrum anti-tumor activity in a variety of solid tumors.

As research continues to deepen, the potential of sunitinib in other advanced or metastatic solid tumors has gradually emerged, such as the exploration of adjuvant therapy for liver cancer and thyroid cancer. Its multi-target mechanism not only inhibits tumor cells, but also intervenes in the tumor microenvironment and angiogenesis, thereby improving therapeutic effects. Doctors can rationally select the sunitinib regimen based on the patient's tumor type, disease course, and tolerance to achieve individualized treatment.

Reference materials:https://www.drugs.com/